Precision BioSciences, Inc. Common Stock DTIL
i
Market dataready · fetched 2026-11-12T01:52:37.426Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:18:46.941264635Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T01:52:37.029014+00:00
Precision BioSciences, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 6.98 | 255.4% | 33.7% | |||
| 25Δ | 7.53 | 270.1% | 30.6% | |||
| 30Δ | 12.08 | 251.4% | 40.2% | 8.08 | 284.7% | 27.5% |
| 35Δ | 11.33 | 236.4% | 32.9% | 8.64 | 299.3% | 24.4% |
| 40Δ | 10.58 | 221.4% | 25.5% | 9.19 | 313.9% | 21.3% |
| 45Δ | 9.89 | 210.9% | 19.5% | 9.74 | 328.5% | 18.2% |
| 50Δ | 9.40 | 215.7% | 17.6% | |||
| 55Δ | 8.92 | 220.6% | 15.8% | |||
| 60Δ | 8.43 | 225.4% | 13.9% | |||
| 65Δ | 7.94 | 230.3% | 12.1% | |||
| 70Δ | 7.46 | 235.1% | 10.3% | |||
| 75Δ | 6.97 | 239.9% | 8.4% | |||
| 80Δ | 6.48 | 244.8% | 6.6% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.98
- IV
- 255.4%
- B/E move
- 33.7%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.53
- IV
- 270.1%
- B/E move
- 30.6%
30Δ
- Pseudo strike
- 12.08
- IV
- 251.4%
- B/E move
- 40.2%
- Pseudo strike
- 8.08
- IV
- 284.7%
- B/E move
- 27.5%
35Δ
- Pseudo strike
- 11.33
- IV
- 236.4%
- B/E move
- 32.9%
- Pseudo strike
- 8.64
- IV
- 299.3%
- B/E move
- 24.4%
40Δ
- Pseudo strike
- 10.58
- IV
- 221.4%
- B/E move
- 25.5%
- Pseudo strike
- 9.19
- IV
- 313.9%
- B/E move
- 21.3%
45Δ
- Pseudo strike
- 9.89
- IV
- 210.9%
- B/E move
- 19.5%
- Pseudo strike
- 9.74
- IV
- 328.5%
- B/E move
- 18.2%
50Δ
- Pseudo strike
- 9.40
- IV
- 215.7%
- B/E move
- 17.6%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 8.92
- IV
- 220.6%
- B/E move
- 15.8%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 8.43
- IV
- 225.4%
- B/E move
- 13.9%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 7.94
- IV
- 230.3%
- B/E move
- 12.1%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 7.46
- IV
- 235.1%
- B/E move
- 10.3%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 6.97
- IV
- 239.9%
- B/E move
- 8.4%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 6.48
- IV
- 244.8%
- B/E move
- 6.6%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 197.13% |
Biotechnology
DYN
Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The…
More →EDIT
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is…
More →ELDN
Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases and amyotrophic lateral…
More →ELTX
Elicio Therapeutics Inc. (ELTX) is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer treatment. Its lead product candidate, Eli-002,…
More →ELVN
Enliven Therapeutics Inc. (Ticker: ELVN) is an innovative biotechnology company focused on transforming cancer therapies and addressing critical healthcare challenges through its…
More →ENGN
Description unavailable
More →